Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

Nesbitt H, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.

Prostate. 2017 Nov;77(15):1539-1547. doi: 10.1002/pros.23434. Epub 2017 Sep 24.

PMID:
28944496
2.

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.

Clin Cancer Res. 2017 Apr 1;23(7):1797-1808. doi: 10.1158/1078-0432.CCR-16-1361. Epub 2016 Oct 3.

3.

Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.

Byrne NM, Nesbitt H, Ming L, McKeown SR, Worthington J, McKenna DJ.

Br J Cancer. 2016 Mar 15;114(6):659-68. doi: 10.1038/bjc.2016.29. Epub 2016 Mar 8.

4.

Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.

Kaur SJ, McKeown SR, Rashid S.

Gene. 2016 Feb 15;577(2):109-18. doi: 10.1016/j.gene.2015.11.049. Epub 2015 Dec 2. Review.

PMID:
26657039
5.

Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE.

Br J Radiol. 2015;88(1056):20150405. doi: 10.1259/bjr.20150405. Epub 2015 Oct 14. Review.

6.

Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.

Nesbitt H, Browne G, O'Donovan KM, Byrne NM, Worthington J, McKeown SR, McKenna DJ.

J Cell Physiol. 2016 Feb;231(2):473-82. doi: 10.1002/jcp.25093.

PMID:
26189652
7.

Radiotherapy for Benign Disease: Current Evidence, Benefits and Risks.

Taylor RE, Hatfield P, McKeown SR, Prestwich RJ, Shaffer R.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):433-5. doi: 10.1016/j.clon.2015.01.009. Epub 2015 Feb 18. Review. No abstract available.

PMID:
25701516
8.

Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

McKeown SR.

Br J Radiol. 2014 Mar;87(1035):20130676. doi: 10.1259/bjr.20130676. Review.

9.

Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.

Bowman KJ, Al-Moneef MM, Sherwood BT, Colquhoun AJ, Goddard JC, Griffiths TR, Payne D, Singh S, Butterworth PC, Khan MA, Summerton DJ, Steward WP, McKelvey-Martin VJ, McKeown SR, Kockelbergh RC, Mellon JK, Symonds RP, Jones GD.

Int J Cancer. 2014 Mar 1;134(5):1102-11. doi: 10.1002/ijc.28437. Epub 2013 Oct 8.

10.

Use of the comet-FISH assay to compare DNA damage and repair in p53 and hTERT genes following ionizing radiation.

McKenna DJ, Doherty BA, Downes CS, McKeown SR, McKelvey-Martin VJ.

PLoS One. 2012;7(11):e49364. doi: 10.1371/journal.pone.0049364. Epub 2012 Nov 7.

11.

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.

Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR, Worthington J.

Br J Cancer. 2012 Nov 6;107(10):1714-21. doi: 10.1038/bjc.2012.455. Epub 2012 Oct 16.

12.

Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.

Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, McKeown SR, Worthington J.

Int J Cancer. 2013 Mar 15;132(6):1323-32. doi: 10.1002/ijc.27796. Epub 2012 Nov 23.

13.

A study of anti-cancer effects of Funalia trogii in vitro and in vivo.

Rashid S, Unyayar A, Mazmanci MA, McKeown SR, Banat IM, Worthington J.

Food Chem Toxicol. 2011 Jul;49(7):1477-83. doi: 10.1016/j.fct.2011.02.008. Epub 2011 Feb 17.

PMID:
21333711
14.

Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation.

Devlin AH, Thompson P, Robson T, McKeown SR.

Mol Carcinog. 2010 Feb;49(2):190-9. doi: 10.1002/mc.20589.

PMID:
19908239
15.

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM, Waugh DJ.

Br J Cancer. 2008 Dec 16;99(12):2054-64. doi: 10.1038/sj.bjc.6604804. Epub 2008 Dec 2.

16.

Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes.

O'Keeffe MB, Devlin AH, Burns AJ, Gardiner TA, Logan ID, Hirst DG, McKeown SR.

Oncol Res. 2008;17(3):93-101.

PMID:
18669161
17.

Cytochrome P450 1B1 expression in rat esophageal tumorigenesis promoted by gastric and duodenal reflux.

Devlin AH, McIlroy M, McKeen HD, Bonde P, Menezes AA, Swarbrick CJ, Robson T, Hirst DG, Campbell FC, McGuigan JA, McKeown SR.

Mol Carcinog. 2009 Feb;48(2):110-7. doi: 10.1002/mc.20459.

PMID:
18618592
18.

Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.

Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J.

Int J Cancer. 2008 Aug 15;123(4):760-8. doi: 10.1002/ijc.23418.

19.

Evaluation of the antiangiogenic potential of AQ4N.

O'Rourke M, Ward C, Worthington J, McKenna J, Valentine A, Robson T, Hirst DG, McKeown SR.

Clin Cancer Res. 2008 Mar 1;14(5):1502-9. doi: 10.1158/1078-0432.CCR-07-1262.

20.

Potential use of the comet assay in the clinical management of cancer.

McKenna DJ, McKeown SR, McKelvey-Martin VJ.

Mutagenesis. 2008 May;23(3):183-90. doi: 10.1093/mutage/gem054. Epub 2008 Feb 5. Review.

PMID:
18256034
21.

Bioreductive drugs: from concept to clinic.

McKeown SR, Cowen RL, Williams KJ.

Clin Oncol (R Coll Radiol). 2007 Aug;19(6):427-42. Epub 2007 May 4. Review.

PMID:
17482438
22.

p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.

McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG, Robson T.

Gene Ther. 2007 Feb;14(3):246-55. Epub 2006 Sep 28.

PMID:
17006546
23.

DNA repair: therapeutic implications.

McKeown SR, Jones B.

Br J Radiol. 2006 Feb;79(938):91-3. No abstract available.

PMID:
16489188
24.

Gene expression in normal urothelium depends on location within the bladder: a possible link to bladder carcinogenesis.

Doherty SC, McKeown SR, Lopez JA, Walsh IK, McKelvey-Martin VJ.

Eur Urol. 2006 Aug;50(2):290-301. Epub 2006 Jan 24.

PMID:
16455181
25.

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2006 Jun;13(6):598-605.

PMID:
16410820
26.

Pericytes influence endothelial cell growth characteristics: role of plasminogen activator inhibitor type 1 (PAI-1).

McIlroy M, O'Rourke M, McKeown SR, Hirst DG, Robson T.

Cardiovasc Res. 2006 Jan;69(1):207-17. Epub 2005 Sep 13.

PMID:
16165110
27.

Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.

Robson T, Worthington J, McKeown SR, Hirst DG.

Technol Cancer Res Treat. 2005 Aug;4(4):343-61. Review.

PMID:
16029055
28.

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR.

J Gene Med. 2005 Jul;7(7):851-9.

PMID:
15712360
29.

Gene-directed enzyme prodrug therapy: a current assessment.

McKeown SR, Ward C, Robson T.

Curr Opin Mol Ther. 2004 Aug;6(4):421-35. Review.

PMID:
15468601
30.

Cell cycle checkpoint function in bladder cancer.

Doherty SC, McKeown SR, McKelvey-Martin V, Downes CS, Atala A, Yoo JJ, Simpson DA, Kaufmann WK.

J Natl Cancer Inst. 2003 Dec 17;95(24):1859-68.

PMID:
14679155
31.

Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells.

Dunne AL, Price ME, Mothersill C, McKeown SR, Robson T, Hirst DG.

Br J Cancer. 2003 Dec 15;89(12):2277-83.

32.

Potential use of the alkaline comet assay as a predictor of bladder tumour response to radiation.

McKeown SR, Robson T, Price ME, Ho ET, Hirst DG, McKelvey-Martin VJ.

Br J Cancer. 2003 Dec 15;89(12):2264-70.

33.
34.

Use of the comet-FISH assay to demonstrate repair of the TP53 gene region in two human bladder carcinoma cell lines.

McKenna DJ, Rajab NF, McKeown SR, McKerr G, McKelvey-Martin VJ.

Radiat Res. 2003 Jan;159(1):49-56.

PMID:
12492368
35.

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2003 Jan;10(1):40-8.

PMID:
12489027
36.

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR.

Br J Cancer. 2001 Aug 17;85(4):625-9. Erratum in: Br J Cancer 2002 Nov 18;87(11):1339.

37.

AQ4N: a new approach to hypoxia-activated cancer chemotherapy.

Patterson LH, McKeown SR.

Br J Cancer. 2000 Dec;83(12):1589-93. Review.

38.

Regulation of FOS by different compartmental stresses induced by low levels of ionizing radiation.

Al-Assar O, Robson T, McKeown SR, Gardin I, Wilson GD, Hirst DG.

Radiat Res. 2000 Nov;154(5):503-14.

PMID:
11025647
39.

Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance.

Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, Hirst DG.

Int J Radiat Biol. 2000 May;76(5):617-23.

PMID:
10866283
40.

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, Stratford IJ.

Br J Cancer. 2000 Jun;82(12):1984-90.

41.

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.

Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S.

Anticancer Drug Des. 1999 Dec;14(6):473-86. Review.

PMID:
10834269
42.

Induction and rejoining of DNA double-strand breaks in bladder tumor cells.

Price ME, McKelvey-Martin VJ, Robson T, Hirst DG, McKeown SR.

Radiat Res. 2000 Jun;153(6):788-94.

PMID:
10825754
43.

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.

Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, Patterson LH, Hirst DG, McKeown SR.

Br J Cancer. 2000 Apr;82(8):1469-73.

44.

Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide.

Ruddock MW, Burns DM, McKeown SR, Murphy L, Walsh IK, Keane PF, Hirst DG.

Radiother Oncol. 2000 Feb;54(2):179-84.

PMID:
10699482
45.

Retinal pericytes control expression of nitric oxide synthase and endothelin-1 in microvascular endothelial cells.

Martin AR, Bailie JR, Robson T, McKeown SR, Al-Assar O, McFarland A, Hirst DG.

Microvasc Res. 2000 Jan;59(1):131-9.

PMID:
10625580
46.

A novel human stress response-related gene with a potential role in induced radioresistance.

Robson T, Joiner MC, Wilson GD, McCullough W, Price ME, Logan I, Jones H, McKeown SR, Hirst DG.

Radiat Res. 1999 Nov;152(5):451-61.

PMID:
10521921
47.

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.

Raleigh SM, Wanogho E, Burke MD, McKeown SR, Patterson LH.

Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):763-7.

PMID:
9845092
49.

An investigation of the radioprotective effect of dietary antioxidants on isolated murine lymphocytes.

Galligan ES, Sweetman SF, Strain SJ, McKeown SR.

Biochem Soc Trans. 1997 Feb;25(1):136S. No abstract available.

PMID:
9057034
50.

Supplemental Content

Loading ...
Support Center